Dr. Mirim Jin, the CEO, was in attendance at the Women’s Bioscience Forum (WBF) Symposium (22nd), which took place on September 21st, and delivered a presentation.
READ MORE
CEO Mirim Jin conducted an interview with HitNews on the topic of “MirimGENE's core pipeline status and future blueprint.""We will leap forward as a biotech that leads the development of innovative new drugs (first-in-class) that can save the lives of autoimmune disease patients around the world. Currently, the manufacturing process (CMC) stage of the lead pipeline (new drug candida...
READ MORE
MirimGENE attended BIO USA 2023 in Boston from June 5th to 8th and was chosen as the presenting company at BIO USA 2023.MirimGENE was also able to connect with numerous global companies such as Novartis, Merck, Pfizer and present our science and technology to them.
READ MORE
On Tuesday, May 30, the Ministry of SMEs and Startups selected 51 ‘Baby Giant Startups (Unicorns)’ that have a high potential to grow into global giant startups (Unicorns). MirimGENE is designated as one of the finalist for Ministry of SMEs and Startups' Baby Unicorn. source : https://mss.go.kr/site/smba/ex/bbs/View.do?cbIdx=86&bcIdx=1042056&parentSeq=1042056&n...
READ MORE
MirimGENE participated in KDRA Bio innovative companies poster zone for the promotion of bio-venture, start-ups, universities, and lab's technologies in part of "KOREA PHARM & BIO 2023", the largest domestic pharm·bio-health industry fair and introduced the excellent Rheumatoid Arthritis treatment effect of WARS1 Neutralizing antibody.
READ MORE